Kefah Mokbel Shares New Insights on Metaplastic Breast Cancer Survival
Kefah Mokbel, Chair of Breast Cancer Surgery at London Breast Institute and Honorary Professor of Medicine at Cardiff University School of Medicine, shared a post on LinkedIn about a paper by Anna M. Chichura et al. published in Annals of Surgical Oncology:
“Despite the retrospective nature of the study, I believe its findings should be practice-changing.
NACT was associated with worse overall survival (OS) in metaplastic breast cancer (MpBC), likely reflecting its chemotherapy-resistant biology and low pathological complete response (pCR) rate. For patients with resectable MpBC, upfront surgery followed by adjuvant chemotherapy and radiotherapy may yield better outcomes. Further research is warranted to define the role of immunotherapy and to develop more effective systemic treatment strategies.”
Title: Neoadjuvant Chemotherapy is Associated with Worse 5-Year Overall Survival in Patients with Metaplastic Breast Cancer Compared with Primary Surgery: A National Cancer Database Analysis
Authors: Anna M. Chichura, Xiaoying Chen, Margo Nelis, Lauren Kopicky, Wei Wei, Azka Ali, Rahul Tendulkar, Zahraa Al-Hilli
You can read the Full Article on Annals of Surgical Oncology.
More posts featuring Kefah Mokbel.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023